Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Roche Partners With UCB On Anti-Tau Alzheimer’s Drug

Jul 29 2020

• By Joseph Haas

Roche takes another shot in Alzheimer's by licensing UCB anti-tau candidate

Related Content

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

Dec 07 2019

TauRx’s Data Massage Can't Work Out The Kinks Of Failed LMTX Study

Jul 28 2016

AC Immune/Roche Drop Crenezumab After Phase III CREAD Alzheimer's Failure

Jan 30 2019

Biogen/Eisai Hit ‘Send’ On High Stakes BLA For Aducanumab In Alzheimer’s Disease

Jul 08 2020

UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline

Feb 26 2020

Another Alzheimer's Setback As Roche And Lilly Drugs Fail

Feb 10 2020

Related Companies

Roche Holding AG

UCB S.A.

Eli Lilly and Company

Washington University

Biogen, Inc.

AC Immune SA

TauRx Therapeutics Ltd.

Additional Topics

Deals Business Strategies Commercial Neurology BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.